{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.26","value":"24.0"},{"groupId":"OG001","spread":"4.07","value":"24.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, PWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.68","value":"23.5"},{"groupId":"OG001","spread":"5.42","value":"23.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, PWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.82","value":"20.9"},{"groupId":"OG001","spread":"5.92","value":"20.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, SWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.95","value":"19.9"},{"groupId":"OG001","spread":"5.31","value":"19.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, SWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.21","value":"18.2"},{"groupId":"OG001","spread":"4.06","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"265"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, EWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.39","value":"18.3"},{"groupId":"OG001","spread":"4.80","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"183"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, EWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.12","value":"17.6"},{"groupId":"OG001","spread":"5.98","value":"17.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"265"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, FWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.24","value":"16.5"},{"groupId":"OG001","spread":"6.19","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, FWB subscale"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.87","value":"47.7"},{"groupId":"OG001","spread":"7.88","value":"47.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, FACT-LymS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.41","value":"48.0"},{"groupId":"OG001","spread":"8.98","value":"48.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"183"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, FACT-LymS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.07","value":"89.3"},{"groupId":"OG001","spread":"15.51","value":"89.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"262"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, FACT-Lymphoma TOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.80","value":"88.0"},{"groupId":"OG001","spread":"18.59","value":"87.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, FACT-Lymphoma TOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.04","value":"80.7"},{"groupId":"OG001","spread":"15.08","value":"80.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"262"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, FACT-G Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.63","value":"78.3"},{"groupId":"OG001","spread":"17.02","value":"77.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, FACT-G Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.81","value":"128.4"},{"groupId":"OG001","spread":"21.27","value":"128.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"261"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, FACT-Lymphoma Total Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.39","value":"126.1"},{"groupId":"OG001","spread":"24.65","value":"125.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, FACT-Lymphoma Total Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"275"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"The FACT-Lymphoma (v4) is composed of 42 items with a 5-point Likert-type scale and 5 subscales. Physical well-being (PWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Social/family well-being (SWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Emotional well-being (EWB) subscale: 6 items measured on 0- to 4-point scale; total score = 0-24. Functional well-being (FWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Lymphoma (LymS) subscale includes 15 items; total score = 0-60. Three total scores can be derived by adding the subscales: FACT-Lymphoma Trial Outcome Index (TOI): (PWB score) + (FWB score) + (LymS score); total score = 0-116. FACT-G total score: (PWB score) + (SWB score) + (EWB score) + (FWB score); total score = 0-108. FACT-Lymphoma total score: (PWB score) + (SWB score) + (EWB score) + (FWB score) + (LymS score); total score = 0-168. The higher the score, the better the quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL: Placebo + Rituximab + Lenalidomide"},{"description":"Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG002","title":"MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG003","title":"MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"MEAN","populationDescription":"FL Full Analysis Set. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to approximately 34 months","title":"FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}